
Neurotrophic Keratopathy - Pipeline Insight, 2025
Description
DelveInsight’s, Neurotrophic Keratopathy - Pipeline Insight, 2025,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Neurotrophic Keratopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Neurotrophic Keratopathy: Overview
Neurotrophic keratitis is a degenerative corneal disease caused by impairment of corneal sensory innervation. It is characterized by decreased or absent corneal sensation, leading to epithelial breakdown, impairment of healing, and ultimately to the development of corneal ulceration, melting and perforation. Ocular and systemic conditions associated with damage at any level to the fifth cranial nerve, from the Trigeminal nucleus to the corneal nerve endings may lead to the development of neurotrophic keratitis. The most common causes include herpetic keratitis, chemical burns, long-term use of contact lenses, corneal surgery, ablative procedures for trigeminal neuralgia, and surgical procedures for reduction of jaw fractures. Other less frequent causes are space-occupying intracranial masses (e.g., schwannoma, meningioma and aneurysms) that can lead to compression of the nerve and reduce corneal sensitivity. Systemic diseases that may compromise trigeminal function like diabetes, multiple sclerosis and Leprosy may lead to the development of neurotrophic keratitis. Presence of neurotrophic keratitis in children is rare and may be seen in association with congenital syndromes like Riley-Day syndrome, Goldenhar- Gorlin syndrome, Mobius syndrome, Familial corneal hypesthesia and Congenital Insensitivity to Pain with Anhidrosis.
""Neurotrophic Keratopathy - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neurotrophic Keratopathy pipeline landscape is provided which includes the disease overview and Neurotrophic Keratopathy treatment guidelines. The assessment part of the report embraces, in depth Neurotrophic Keratopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurotrophic Keratopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Neurotrophic Keratopathy Drugs
Further product details are provided in the report……..
Neurotrophic Keratopathy: Therapeutic Assessment
This segment of the report provides insights about the Neurotrophic Keratopathy drugs segregated based on following parameters that define the scope of the report, such as:
Neurotrophic Keratopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neurotrophic Keratopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neurotrophic Keratopathy drugs.
Neurotrophic Keratopathy Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Neurotrophic Keratopathy: Overview
Neurotrophic keratitis is a degenerative corneal disease caused by impairment of corneal sensory innervation. It is characterized by decreased or absent corneal sensation, leading to epithelial breakdown, impairment of healing, and ultimately to the development of corneal ulceration, melting and perforation. Ocular and systemic conditions associated with damage at any level to the fifth cranial nerve, from the Trigeminal nucleus to the corneal nerve endings may lead to the development of neurotrophic keratitis. The most common causes include herpetic keratitis, chemical burns, long-term use of contact lenses, corneal surgery, ablative procedures for trigeminal neuralgia, and surgical procedures for reduction of jaw fractures. Other less frequent causes are space-occupying intracranial masses (e.g., schwannoma, meningioma and aneurysms) that can lead to compression of the nerve and reduce corneal sensitivity. Systemic diseases that may compromise trigeminal function like diabetes, multiple sclerosis and Leprosy may lead to the development of neurotrophic keratitis. Presence of neurotrophic keratitis in children is rare and may be seen in association with congenital syndromes like Riley-Day syndrome, Goldenhar- Gorlin syndrome, Mobius syndrome, Familial corneal hypesthesia and Congenital Insensitivity to Pain with Anhidrosis.
""Neurotrophic Keratopathy - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neurotrophic Keratopathy pipeline landscape is provided which includes the disease overview and Neurotrophic Keratopathy treatment guidelines. The assessment part of the report embraces, in depth Neurotrophic Keratopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurotrophic Keratopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Neurotrophic Keratopathy R&D. The therapies under development are focused on novel approaches to treat/improve Neurotrophic Keratopathy.
Neurotrophic Keratopathy Drugs
- OC-01: Epizyme
Further product details are provided in the report……..
Neurotrophic Keratopathy: Therapeutic Assessment
This segment of the report provides insights about the Neurotrophic Keratopathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Neurotrophic Keratopathy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intranasal
- Intrathecal
- Intravenous
- Oral
- Oral/Intravenous
- Parenteral
- Subcutaneous
- Subcutaneous/Intramuscular
- Transdermal
- Molecule Type
- Antisense oligonucleotide
- Gene therapy
- Hormones
- Neuropeptides
- Oligonucleotides
- Small Molecule
- Triglyceride
- Product Type
Neurotrophic Keratopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neurotrophic Keratopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neurotrophic Keratopathy drugs.
Neurotrophic Keratopathy Report Insights
- Neurotrophic Keratopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Neurotrophic Keratopathy drugs?
- How many Neurotrophic Keratopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neurotrophic Keratopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neurotrophic Keratopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Neurotrophic Keratopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- RegeneRx Biopharmaceuticals
- RECORDATI
- Oyster Point Pharma
- Oculis
- Gtree Pharmaceuticals
- Dompé Farmaceutici
- Claris Biotherapeutics
- RGN-259
- REC 0559
- OC-01
- OCS-05
- NRO-1
- GBT-201
- rhNGF
- CSB-001
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Neurotrophic Keratopathy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Neurotrophic Keratopathy– DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase III)
- Comparative Analysis
- RGN-259: RegeneRx Biopharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- OC-01: Oyster Point Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- NRO-1: Gtree Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Neurotrophic Keratopathy Key Companies
- Neurotrophic Keratopathy Key Products
- Neurotrophic Keratopathy- Unmet Needs
- Neurotrophic Keratopathy- Market Drivers and Barriers
- Neurotrophic Keratopathy- Future Perspectives and Conclusion
- Neurotrophic Keratopathy Analyst Views
- Neurotrophic Keratopathy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.